Jason Zhaoxing Zhang

Jason Zhaoxing Zhang

Auto-generated profile, based on publicly available information

Jason Zhaoxing Zhang

Department of Biochemistry, University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2023 in Nature
Verified
Journal Article
Open access
PDF file
HYHsien Wei Yeh
Hsien Wei Yeh
CNChristoffer Norn
Christoffer Norn
YKYakov Kipnis
Yakov Kipnis
DTDoug Tischer
Doug Tischer
SPSamuel J. Pellock
Samuel J. Pellock
DBDavid Baker
David Baker
De novo enzyme design has sought to introduce active sites and substrate-binding pockets that are predicted to catalyse a reaction of interest into geometrically compatible native scaffolds1,2, but has been limited by a lack of suitable protein structures and the complexity of native protein sequence–structure relationships. Here we describe a deep-learning-based ‘family-wide hallucination’ approach that generates large numbers of idealized protein structures containing diverse pocket shapes and designed sequences that encode them. We use these scaffolds to design artificial luciferases that selectively catalyse the oxidative chemiluminescence of the synthetic luciferin substrates diphenylterazine3 and 2-deoxycoelenterazine. The designed active sites position an arginine guanidinium group adjacent to an anion that develops during the reaction in a binding pocket with high shape complementarity. For both luciferin substrates, we obtain designed luciferases with high selectivity; the most active of these is a small (13.9 kDa) and thermostable (with a melting temperature higher than 95 °C) enzyme that has a catalytic efficiency on diphenylterazine (kcat/Km = 106 M−1 s−1) comparable to that of native luciferases, but a much higher substrate specificity. The creation of highly active and specific biocatalysts from scratch with broad applications in biomedicine is a key milestone for computational enzyme design, and our approach should enable generation of a wide range of luciferases and other enzymes.

25 August 2020 in Cell
Verified
Journal Article
Closed access
JZJason Z. Zhang
Jason Z. Zhang
TLTsan-Wen Lu
Tsan-Wen Lu
LSLucas Martins Stolerman
Lucas Martins Stolerman
BTBrian Tenner
Brian Tenner
JYJessica R. Yang
Jessica R. Yang
JZJin Zhang
Jin Zhang

25 September 2024 in Nature
Verified
Journal Article
Open access
PDF file
BHBuwei Huang
Buwei Huang
MAMohamad Abedi
Mohamad Abedi
GAGreen Ahn
Green Ahn
BCBrian Coventry
Brian Coventry
ISIsaac Sappington
Isaac Sappington
DBDavid Baker
David Baker
Endocytosis and lysosomal trafficking of cell surface receptors can be triggered by endogenous ligands. Therapeutic approaches such as lysosome-targeting chimaeras1,2 (LYTACs) and cytokine receptor-targeting chimeras3 (KineTACs) have used this to target specific proteins for degradation by fusing modified native ligands to target binding proteins. Although powerful, these approaches can be limited by competition with native ligands and requirements for chemical modification that limit genetic encodability and can complicate manufacturing, and, more generally, there may be no native ligands that stimulate endocytosis through a given receptor. Here we describe computational design approaches for endocytosis-triggering binding proteins (EndoTags) that overcome these challenges. We present EndoTags for insulin-like growth factor 2 receptor (IGF2R) and asialoglycoprotein receptor (ASGPR), sortilin and transferrin receptors, and show that fusing these tags to soluble or transmembrane target protein binders leads to lysosomal trafficking and target degradation. As these receptors have different tissue distributions, the different EndoTags could enable targeting of degradation to different tissues. EndoTag fusion to a PD-L1 antibody considerably increases efficacy in a mouse tumour model compared to antibody alone. The modularity and genetic encodability of EndoTags enables AND gate control for higher-specificity targeted degradation, and the localized secretion of degraders from engineered cells. By promoting endocytosis, EndoTag fusion increases signalling through an engineered ligand–receptor system by nearly 100-fold. EndoTags have considerable therapeutic potential as targeted degradation inducers, signalling activators for endocytosis-dependent pathways, and cellular uptake inducers for targeted antibody–drug and antibody–RNA conjugates.

28 September 2020 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
JZJin-Fan Zhang
Jin-Fan Zhang
BLBian Liu
Bian Liu
IHIngie Hong
Ingie Hong
AMAlbert Mo
Albert Mo
RRRichard H. Roth
Richard H. Roth
JZJin Zhang
Jin Zhang

29 April 2026 in Nature
Verified
Journal Article
Closed access
PDF file
WYWei Yang
Wei Yang
SWShunzhi Wang
Shunzhi Wang
GLGyu Rie Lee
Gyu Rie Lee
JZJason Z. Zhang
Jason Z. Zhang
ACAlexis Courbet
Alexis Courbet
DBDavid Baker
David Baker

9 May 2024 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
EYErin C. Yang
Erin C. Yang
RDRobby Divine
Robby Divine
MMMarcos C. Miranda
Marcos C. Miranda
ABAndrew J. Borst
Andrew J. Borst
WSWill Sheffler
Will Sheffler
DBDavid Baker
David Baker
Programming protein nanomaterials to respond to changes in environmental conditions is a current challenge for protein design and is important for targeted delivery of biologics. Here we describe the design of octahedral non-porous nanoparticles with a targeting antibody on the two-fold symmetry axis, a designed trimer programmed to disassemble below a tunable pH transition point on the three-fold axis, and a designed tetramer on the four-fold symmetry axis. Designed non-covalent interfaces guide cooperative nanoparticle assembly from independently purified components, and a cryo-EM density map closely matches the computational design model. The designed nanoparticles can package protein and nucleic acid payloads, are endocytosed following antibody-mediated targeting of cell surface receptors, and undergo tunable pH-dependent disassembly at pH values ranging between 5.9 and 6.7. The ability to incorporate almost any antibody into a non-porous pH-dependent nanoparticle opens up new routes to antibody-directed targeted delivery.